Coultreon Biopharma closed an oversubscribed $125 million Series A to push its lead oral SIK3 inhibitor, COL-5671, from Phase 1 into Phase 2 studies in psoriasis and ulcerative colitis, targeting clinical proof-of-concept in 2027. The financing was led by Sofinnova Investments with Forbion and Novo Holdings as co-leads; the syndicate includes Galapagos, Regeneron Ventures, Balyasny, Luma Group, Samsara BioCapital, Longwood Fund, and Finchley Healthcare Ventures. The asset originated at Galapagos and was transferred to Coultreon in 2025.
The move formalizes a strategic pivot for the company, previously Onco3R Therapeutics, into immunology with a first-in-class target. COL-5671 selectively inhibits SIK3 to reduce transcription of pro-inflammatory cytokines like TNFα and IL-23 while increasing IL-10. Early clinical and preclinical work point to once-daily pharmacokinetics and biomarker suppression consistent with the mechanism, providing enough signal to justify parallel expansion into dermatology and IBD. The selection of psoriasis and ulcerative colitis is tactically sound: psoriasis offers fast, interpretable PASI readouts with manageable procedures, while ulcerative colitis provides higher unmet need and differentiation potential if endoscopic and symptomatic endpoints align.
The underlying bet is that a highly selective SIK3 approach can bypass the trade-offs that have complicated other oral immunomodulators, delivering broad anti-inflammatory control without the safety baggage regulators are scrutinizing across the class. That is not yet proven. Prior SIK programs have produced uneven translational results, and the bar in both target indications has risen. Psoriasis now features effective oral competitors and dominant IL-23/IL-17 biologics; ulcerative colitis has accelerated uptake of small molecules and newer biologics with strong mucosal healing profiles. Coultreon will need a clear efficacy and tolerability delta to justify share in crowded protocols and, later, in formularies.
For sites and CROs, this is a multi-indication, biomarker-rich program well suited to networked execution. Oral, once-daily dosing reduces infusion chair dependencies and supports decentralized follow-up, but UC trials will still require endoscopy, central reading, and strict biopsy handling. Recruitment will be the operational choke point in IBD, where competition for moderate-to-severe patients is intense; psoriasis enrollment should move faster, particularly if inclusion criteria avoid heavy biomarker gating. The absence of mandatory pre-screen testing could ease startup, but sponsors will be expected to embed translational endpoints—cytokine panels, fecal calprotectin, CRP, tissue pharmacodynamics—to substantiate on-target activity and dose selection. Vendors focused on ePROs, adherence monitoring, and centralized histopathology will find near-term opportunity.
Regulators will look for class-wide risk management and breadth of safety exposure, given the mechanism’s immunologic reach. Clean hepatic, hematologic, and infection profiles in Phase 1 and dose-ranging Phase 2 will be essential, as will demonstration of durable effects beyond short biomarker windows. The financing size should carry Coultreon through parallel Phase 2 programs and into an options-rich 2027 inflection, with a syndicate that can support rapid partnering if signals warrant.
Key watch items over the next 12–18 months include Phase 1 multiple-ascending dose data with pharmacodynamic readouts, the Phase 2 designs and powering assumptions in psoriasis and UC, handling of endoscopic endpoints and central reads in UC, and any early signals that SIK3 selectivity translates into a distinct safety profile. The unresolved question is whether SIK3 modulation can deliver efficacy on par with current standards while maintaining a cleaner risk profile than other orals. If the translational story holds, Coultreon can credibly scale across additional IMIDs; if not, the program risks being bracketed by faster-following TYK and JAK incumbents.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
